Evidence map›Paper›PMID 25073959›Full record

ArticleExperimental biology and medicine (Maywood, N.J.)2015

Apolipoprotein polymorphism is associated with pro-thrombotic profile in non-demented dyslipidemic subjects.

Cláudia N Ferreira, Maria G Carvalho, Karina B Gomes, Helton J Reis, Ana-Paula Fernandes, András Palotás, Marinez O Sousa

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental biology and medicine (Maywood, N.J.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Cláudia N FerreiraUniversidade Federal de Minas Gerais, Belo Horizonte, 31270-901, Brazil.
Maria G CarvalhoUniversidade Federal de Minas Gerais, Belo Horizonte, 31270-901, Brazil.
Karina B GomesUniversidade Federal de Minas Gerais, Belo Horizonte, 31270-901, Brazil.
Helton J ReisUniversidade Federal de Minas Gerais, Belo Horizonte, 31270-901, Brazil.
Ana-Paula FernandesUniversidade Federal de Minas Gerais, Belo Horizonte, 31270-901, Brazil.
András PalotásAsklepios-Med (private medical practice and research center), Szeged, H-6722, Hungary palotas@asklepios-med.eu.
Marinez O SousaUniversidade Federal de Minas Gerais, Belo Horizonte, 31270-901, Brazil.
Universidade Federal de Minas Gerais · BRAsklepios · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Apolipoprotein gene polymorphism has an important role in lipid metabolism and in the development of cerebro- and cardio-vascular disease (CCVD), including dementia. Dyslipidemia and hemostatic abnormalities are key risk factors associated with athero-sclerotic events preceding CCVD. The aim of this study was to evaluate the possible relationships of various apolipoprotein-species with hemostatic parameters and cognitive function. Lipid profile, gene polymorphism, coagulation markers, and mini-mental state examination (MMSE) scores were assessed in 109 dys-lipidemic subjects and in 107 healthy control volunteers. Thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels were significantly higher in apolipoprotein-E2 (apoE2) patients when compared to other apoE forms. The apoA5 -1131T>C polymorphism was associated with elevated D-dimer concentration in dyslipidemic TT homozygous individuals. MMSE did not correlate with lipid or coagulation profile. These data suggest that apoE and apoA5 variants have an effect on hemostatic parameters, but they neither influence nor predict cognitive performance in non-demented individuals.

Indexed as

Genetic Predisposition to DiseasePolymorphism, GeneticAdultApolipoprotein A-VApolipoproteins AApolipoproteins EDementiaDyslipidemiasFemaleHumansMaleMiddle AgedThrombosisAPOA5 protein, humanApolipoprotein A-VApolipoproteins AApolipoproteins EApolipoprotein-A5 (apoA5)apolipoprotein-E (apoE)cerebro- and cardio-vascular disease (CCVD)cognitive performanceD-dimerdementiadyslipidemiagene polymorphismthrombin-activatable fibrinolysis inhibitor (TAFI)

Identifiers

PMID25073959
PMCPMC4935188
OpenAlexW2031569781

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.